CClinicalTrials.gg
Status unknownNCT04715308Pelvex 3Updated Feb 10, 2021

Patient Experiences Following Urinary Diversion as Part of Surgery for Advanced and Recurrent Rectal Cancer

An observational study in Patient Satisfaction, Quality of Life and Patient Participation, sponsored by St Vincent's University Hospital, Ireland. Status unknown at 1 site in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by St Vincent's University Hospital, Ireland · Observational

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Study summary

The outcomes of patients who undergo radical surgery for locally advanced and recurrent rectal cancer have improved vastly, but there is a lack of emphasis on the quality-of-life outcomes of these patients. This study will assess the patient experience of having a stoma for urinary diversion as part of surgery for advanced pelvic malignancy. This will be assessed at regular intervals both before and after surgery with the goal of increasing awareness of patient beliefs and concerns with regards to their stomas and to devise interventions that will improve their quality-of-life.

Read the detailed description

Considerable progress has been made in the management of advanced and recurrent pelvic cancer over the last few decades. However, much emphasis has been placed on surgical and hospital-related outcomes. In recent years, there has been an increased focus on patient quality-of-life following major abdominopelvic surgery. However, there is a lack of updated evidence on how patients manage and perceive their stomas. Managing a stoma is a difficult task for patients and can adversely effect their quality-of-life. This study will investigate specifically the impact of managing a urostomy or ileal conduit. Patients will be contacted via an anonymized, opt-in SMS or email to answer a questionnaire, having previously been provided with a patient information leaflet. This will take approximately 5 minutes to complete and will be carried out just prior to and at 1, 3, 6, 9 and 12 months post-operatively. All of this data will be collated and published as part of a wider investigation in to patient quality-of-life following major abdominal and pelvic surgery. This study will be carried out in 35 countries.

02

Conditions studied

  • Patient Satisfaction
  • Quality of Life
  • Patient Participation

Browse trials for

Keywords

  • Rectal cancer
  • Locally advanced and recurrent rectal cancer
  • Advanced pelvic cancer
  • Urinary diversion for rectal cancer
  • Quality of life
03

In context

Rectal Neoplasms

1,762 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 160 across 413 observational studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

St Vincent's University Hospital, Ireland is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cohort of patients who are undergoing surgery for locally advanced or recurrent rectal cancer and are undergoing a urinary diversion or reconstruction.

Inclusion criteria

  • Histologically-proven advanced rectal cancer
  • Has undergone urinary diversion/reconstruction
  • Aged 18 years or older
  • Able and willing to give written, informed consent
  • Able to access email/internet

Exclusion criteria

Exclusion Criteria:

  • Strong evidence of metastatic or peritoneal disease
  • Palliative exenteration
  • Non-rectal origin of primary tumour
  • Colonic obstruction
  • Inability to answer online questionnaire
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No

Interventions

  • ProcedureUrinary diversion

    The formation of a stoma to divert urine to the skin because of the need to resect the bladder as part of surgery for advanced pelvic malignancy

06

What researchers measure

Primary outcomes

  1. To determine the 30-day complication rate of urinary diversion/reconstruction following pelvic exenteration

    Morbidity of urinary diversion/reconstruction

    Time frame: 2 years

  2. To assess the impact of urinary diversion/reconstruction subtypes on quality-of-life

    Patient-reported outcomes assessing their quality-of-life

    Time frame: Before surgery and at 1, 3, 6, 9 and 12 months respectively

Secondary outcomes

  1. To assess the longer-term complications associated with urinary diversion/reconstruction

    Morbidity of urinary diversion or reconstruction over longer than 1 month but less than 1 year

    Time frame: 1 month - 12 months

  2. To measure the rate of reintervention for complications associated with urinary diversion/reconstruction

    Rate of reintervention

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No individual patient date other than their responses to the questionnaire will be collected or shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04715308
Lead sponsor
St Vincent's University Hospital, Ireland
Responsible party
Professor Des Winter (Professor Des C Winter, Consultant Gastronitestinal Surgeon, St Vincent's University Hospital, Ireland) — Principal investigator
First posted
Jan 20, 2021
Start date
Dec 1, 2020
Primary completion
Dec 1, 2021 (estimated)
Completion
Mar 1, 2022 (estimated)
Last update
Feb 10, 2021

Study contacts

Matthew Fahy, MB
Contact
MFahy94@gmail.com
00353874510237
Michael Kelly, MD
Contact
kellym11@tcd.ie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion